HD-OPM Archive
Topics › Supplements & vitamins

Omega-3 supplementation across 40 RCTs lowered heart attack 13% and fatal heart attack 35%

Louis Nervegna · Dec 20, 2025 · ♥ 23 reactions · 26 comments · original Facebook post
Supplements & vitaminsHeart attack, stroke & procedures
AI summary & key facts

A 2021 meta-analysis of 40 randomized trials in 135,267 participants found omega-3 EPA/DHA reduced several cardiac outcomes, with suggested doses of 1000-2000 mg.

Effect of Omega-3 Dosage on Cardiovascular Outcomes

An Updated Meta-Analysis and Meta-Regression of Interventional Trials, Feb. 2021

In aggregate, 40 randomized trials on 135,267 participants demonstrate that supplementation with omega 3 fatty acids (EPA/DHA) reduces risk of heart attack by 13%, risk of coronary heart disease (CHD) events by 10%, fatal heart attacks by 35%, and CHD mortality by 9%.

The reduction in fatal heart attacks by 35% is especially impressive, in comparison to other interventions.

In the conclusion of the paper, the authors suggest a dose of 1000-2000mg of combined EPA/DHA for prevention of CVD.

WARNING: Several RCT’s have demonstrated a small increased risk of AFIB at high doses of omega 3 supplementation. Please talk to your cardiologist before taking high doses of fish oil, especially if you are at increased risk for developing AFIB.

Quoted:

“Cardiovascular disease remains the leading cause of death worldwide. Supplementation with EPA and DHA is an effective lifestyle strategy for CVD prevention, and the protective effect probably increases with dosage.”

“This is an update and expanded analysis of a previously published meta-analysis which covers all randomized control trials with EPA/DHA interventions and cardiovascular outcomes published before August 2019. The outcomes included are myocardial infarction (MI), coronary heart disease (CHD) events, CVD events (a composite of MI, angina, stroke, heart failure, peripheral arterial disease, sudden death, and non-scheduled cardiovascular surgical interventions), CHD mortality and fatal MI.”

“A total of 40 studies with a combined 135,267 participants were included. Supplementation was associated with reduced risk of MI (relative risk [RR], 0.87; 95% CI, 0.80 to 0.96), high certainty number needed to treat (NNT) of 272; CHD events (RR, 0.90; 95% CI, 0.84 to 0.97), high certainty NNT of 192; fatal MI (RR, 0.65; 95% CI, 0.46 to 0.91]), moderate certainty NNT = 128; and CHD mortality (RR, 0.91; 95% CI, 0.85 to 0.98), low certainty NNT = 431, but not CVD events (RR, 0.95; 95% CI, 0.90 to 1.00). The effect is dose dependent for CVD events and MI.”

“Use of EPA and DHA was also associated with a statistically significant (P<.001) lower risk of CHD events and MI with equivalent risk reductions of 9% (95% CI, -16% or -3%) and 13% (-20%; -4%), respectively. In the case of MI, this risk reduction is dose-dependent, and each additional 1 g/day is associated with a significant risk reduction of 9.0%. These findings indicate that long-chain marine omega-3s are an effective strategy for the prevention of CHD events, and especially protective against MI.”

“Conclusion - The current study presents strong evidence that EPA+DHA supplementation is an effective strategy for the prevention of certain CVD outcomes, and that for CVD events and MI the protective effect appears to increase with dosage. Authoritative bodies issuing intake recommendations and health care providers need to consider taking these results into account. Considering the relatively low costs and side effect profiles of omega-3 supplementation and the low drug-drug interactions with other standard therapies used in primary and secondary CVD prevention, clinicians and patients should consider the potential benefits of omega-3 (EPA/DHA) supplementation, especially using 1000 to 2000 mg/day dosages, which are rarely obtained in most Westernized diets, even those including some routine fish consumption.”

mayoclinicproceedings.orgS0025 6196(20)30985 Xmayoclinicproceedings.org

#omegaHD #fishoilHD #seafoodHD #fishHD #epaHD #dhaHD

Paper · Mayo Clinic Proceedings · 2021Effect of Omega-3 Dosage on Cardiovascular OutcomesTo quantify the effect of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on cardiovascular disease (CVD) prevention and the effect of dosage.mayoclinicproceedings.org

Research cited

← newer: Keeping blood pressure below 130/80 linked to 15% lower demeolder: Insulin resistance alone doesn't cause type 2 diabetes; fail →